Two protein inhibitors of the VEGFA pathway—aflibercept, a recombinant VEGFR fusion protein that binds to and inhibits VEGFA, VEGFB, and PIGF21, and ramucirumab, a fully human monoclonal antibody that inhibits VEGFR2—have been approved for use in cancer therapy in addition to bevacizumab and small-molecule RTKIs [259]. Here, VEGFB is linked to cancer.